Kindbody's $32M Series B for women's health, K4Connect's $7.7M for senior tech and more digital health funding news

Also: Truepill to expand digital pharmacy business with $25 million Series B; Nucleai's precision oncology platform gains $6.5 million from Debiopharm.
By Dave Muoio
12:01 pm

Kindbody, a women's health startup combining virtual care with face-to-face visits, raised $32 million in Series B funding. Perceptive Advisors led the round, which also saw support from prior backers RRE, GV and Freemark Capital, as well as new investors Rock Springs Capital, Goodgrower, Claritas Capital and NFP.

The startup said it would be using its new funding to expand its owned physical locations and network of partner clinics, both in the U.S. and internationally. The company said that it currently has delivered care at 180 of these locations so far.

"You must be in the provision of services – in the actual care delivery business – to effectuate change in member experience, outcomes and costs. Sophisticated employers know this and are helping to drive change, utilizing their buying power to control costs. We're fortunate to have blue-chip investors to help accelerate this," Gina Bartasi, founder and CEO of Kindbody, said in a statement. "The funds allow us to scale the infrastructure – in terms of people and process – required to execute on large accounts. We're adding depth to our outstanding team at almost every level."

Senior and disability technology startup K4Connect announced a new $7.7 million investment led by Forte Ventures, which the company said will close out its multi-year Series B round at $21 million. This brings the K4Connect to $31 million in total funding.

The company said that its new funds will speed up the development and deployment of new connected technologies for older adults. Currently, its technology is being employed by more than 800 continuing care, independent living and assisted living communities across the U.S.

“We are thrilled to lead this round of funding to support all that K4Connect is doing to serve the older adult community and the senior living industry,” Louis Rajczi, partner at Forte Ventures, said in a statement. “This is a particularly exciting partnership for us as we are passionately behind K4Connect’s vision of improving the lives of the nation’s older adults through innovation. Forte Ventures focuses on opportunities where strategic investment will push industries forward, and K4Connect is clearly leading the innovation movement in the senior living segment.” 

Truepill – a digital pharmacy that focuses on APIs, telehealth practitioners and pharmacy fulfillment services – has brought in $25 million in Series B funding. TI Platform Fund, Optum Ventures, Initialized Capital, Sound Ventures and other unnamed backers took part in the round.

The company said that it will be working to expand its product offerings; improve its integrated, direct-to-patient products; and generally meet the "increasing demand" for its services within the U.S.

"We are working with our partners to deliver the most innovative healthcare experiences for patients," Sid Viswanathan, Truepill cofounder and president, said in a statement. "We are excited to see our API-connected infrastructure being leveraged across the entire healthcare ecosystem. We see a future where over 80% of healthcare visits will be performed using telehealth or a digital experience, and we are positioning Truepill to be the platform building that future."

Nucleai, the maker of an AI platform for precision oncology research and treatment decision-making, has closed a Series A raise of $6.5 million led by Swiss biopharma company Debiopharm.

In addition to a research collaboration that it will be starting with its new patron, the Israeli startup plans to continue development on its platform and expand commercial reach to potential pharma and biotech business partners.

Debiopharm is bringing decades of pharmaceutical expertise, which will assist in accelerating our development and market reach," Avi Veidman, CEO of Nucleai, said in a statement. "Nucleai has multiple revenue-generating, commercial partnerships, with leading Immunotherapies pharma companies and US-based payors. We plan to use these funds to expand our offering to additional indications and diseases as well as to increase our commercial footprint substantially."


The latest news in digital health delivered daily to your inbox.

Thank you for subscribing!
Error! Something went wrong!